Schwartz's background as a physician with plenty of government service experience will likely be popular among lawmakers.

Arbitration decisions, it turns out, are like cockroaches. They’re very hard to kill.  It’s a long held truism in the legal ...

Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't ...

The FDA is revisiting its stance on compounded peptides with plans for advisory panel meetings. Also, a sweeping Cochrane ...

This week, the FDA flexed its regulatory authority to approve the first medicine to treat focal segmental glomerulosclerosis, ...

Roche is launching a Phase 3 trial of the controversial Duchenne gene therapy Elevidys, hoping it could lead to approval in ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

This week on "The Readout LOUD," a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in ...

Kennedy Jr. returned to Capitol Hill Thursday, where he defended the administration’s efforts to fight health care fraud and ...

RFK Jr. will have to walk a careful line between touting his MAHA wins and avoiding talking about his politically divisive ...

The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain ...

CMS may change breakthrough device payments, Zealthy's legal troubles, and more.